KYNTHEUM (brodalumab), interleukin inhibitor immunosuppressant

High clinical benefit for the treatment of severe chronic plaque psoriasis in adults defined by:

• failure of at least two treatments including non-biological systemic treatments and light therapy

• and an extensive form and/or significant psychosocial impact

but no proven clinical added value compared to COSENTYX and TALTZ.

Insufficient clinical benefit to justify reimbursement for other forms.

•  KYNTHEUM is an IL17 receptor A inhibitor that has been granted a marketing authorisation for moderate to severe plaque psoriasis in adults requiring systemic treatment.

• Similar to the other IL17 antagonists, COSENTYX and TALTZ, it has demonstrated its superiority over STELARA.

• KYNTHEUM is a systemic treatment to be reserved for the treatment of plaque psoriasis in adults, for patients with severe, chronic plaque psoriasis, defined by:

• failure (insufficient response, contraindication or intolerance) of at least two treatments including non-biological systemic treatments and light therapy

• and an extensive form and/or significant psychosocial impact.